Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1,560 MXN
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:10 PM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

johnson & johnson (JNJ*) Snapshot

Open
$1,560
Previous Close
$1,560
Day High
$1,560
Day Low
$1,560
52 Week High
04/27/15 - $1,580
52 Week Low
05/27/14 - $1,260
Market Cap
4.3T
Average Volume 10 Days
522.2
EPS TTM
--
Shares Outstanding
2.8B
EX-Date
05/21/15
P/E TM
--
Dividend
$3.00
Dividend Yield
2.61%
Current Stock Chart for JOHNSON & JOHNSON (JNJ*)

johnson & johnson (JNJ*) Details

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON’S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women’s health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages and first aid products under the BAND-AID and NEOSPORIN brand names; and nutritional products comprising no calorie sweetener under the SPLENDA brand name. This segment also offers over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic, and trauma and neurological products; general surgery, and biosurgical and energy products; products to treat cardiovascular disease; infection prevention products; diagnostics products; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company distributes its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.

126,500 Employees
Last Reported Date: 02/24/15
Founded in 1885

johnson & johnson (JNJ*) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $1.5M
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $878.1K
Worldwide Chairman of Pharmaceuticals, Chief ...
Total Annual Compensation: $1.1M
Group Worldwide Chairman and Member of Execut...
Total Annual Compensation: $841.3K
Vice President, General Counsel and Member of...
Total Annual Compensation: $591.3K
Compensation as of Fiscal Year 2014.

johnson & johnson (JNJ*) Key Developments

Johnson & Johnson Announces Boar Changes

Johnson & Johnson announced that the decision of Stephen J. Cosgrove, Controller and Chief Accounting Officer of the company, to retire in October 2015. Upon Mr. Cosgrove's retirement, Ronald A. Kapusta will become Controller and Chief Accounting Officer of the company. Mr. Kapusta, 56, joined the company in 1992 and held a number of finance positions within the company's Consumer segment over the next nine years, including Operations Controller for the company's former subsidiary, McNeil Consumer Products Company, and Vice President, Finance, Worldwide Nutritionals. From 2001 to 2006, Mr. Kapusta served as Vice President, Finance for the Registrant's former subsidiary, Ortho-Clinical Diagnostics Inc., and then Vice President, Finance for the DePuy Orthopaedics Inc.

Johnson & Johnson Agrees to Pay About $7.8 Million to Settle A 71/2-Year-Old Lawsuit

Johnson & Johnson has agreed to pay about $7.8 million to settle a 71/2-year-old lawsuit by the state over how the company had marketed its popular anti-psychotic Risperdal to Arkansas doctors. Of that amount, $2 million will go to the Texas law firm that represented Arkansas in the Medicaid-fraud and deceptive-marketing lawsuit initiated in November 2007. The legal-services payment required the approval of Pulaski County Circuit Judge Tim Fox, who presided over the litigation. He signed off on the payment agreement in a two-page ruling that also described the state's settlement with the drugmaker. The judge had ordered the sides to attempt mediation earlier this month. The remaining $5,750,000 payout to the state is less than 1% of the $1.2 billion fine that had been imposed on Johnson & Johnson after a 12-day trial three years ago in which a Pulaski County jury found that the company, through its Janssen Pharmaceutical subsidiary, had committed Medicaid fraud and violated the state Deceptive Trade Practices Act in its labeling and marketing of Risperdal.

Johnson & Johnson Presents at BioEquity Europe 2015, May-19-2015 11:00 AM

Johnson & Johnson Presents at BioEquity Europe 2015, May-19-2015 11:00 AM. Venue: InterContinental Vienna, Vienna, Austria. Speakers: Jeanne Bolger, Vice President of Venture Investments.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JNJ*:MM $1,560.00 MXN 0.00

JNJ* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $27.68 USD -0.04
Novartis AG SFr.98.10 CHF +0.05
Pfizer Inc $34.28 USD -0.08
Roche Holding AG SFr.277.90 CHF -1.30
Procter & Gamble Co/The $79.95 USD -0.46
View Industry Companies
 

Industry Analysis

JNJ*

Industry Average

Valuation JNJ* Industry Range
Price/Earnings 18.4x
Price/Sales 3.9x
Price/Book 4.2x
Price/Cash Flow 17.8x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JOHNSON & JOHNSON, please visit www.jnj.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.